Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Genosera","sponsor":"Solve GNE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Genosera

    Menu

    Genosera

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Genosera

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM

              Details:

              The funding will be used for a novel Adeno-Associated Virus (AAV) gene therapy, GA-002, aimed at curing GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM).

              Lead Product(s): GA-002

              Therapeutic Area: Rare Diseases and Disorders Product Name: GA-002

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Solve GNE

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY